GlassScriptPhysician profile
Jack J Rodriguez
NPI 1184623886
$13,728.19
in general payments reported to CMS, 2019-2025
64 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $1,574 · 2021: $2,205 · 2022: $2,215 · 2023: $2,072 · 2024: $1,815 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,288 · Education: $187 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.95 |
| Education | $186.99 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,955.70 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $1,427.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,407.78 | 2019-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $1,007.20 | 2019-2024 | Enhertu, Calquence |
| Astellas Pharma US INC | $743.87 | 2019-2025 | Xtandi, Padcev, Xospata |
| Merck Sharp & Dohme LLC | $578.06 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Puma Biotechnology, INC. | $505.31 | 2019-2025 | Nerlynx |
| Genentech USA, INC. | $431.12 | 2019-2023 | Perjeta, Phesgo, Kadcyla |
| Genzyme Corporation | $395.70 | 2019-2023 | |
| Amgen INC. | $369.79 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $354.16 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $321.15 | 2019-2024 | Somatuline Depot, Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $305.25 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Beigene USA, INC. | $253.33 | 2020-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $239.40 | 2020-2025 | Ojjaara, Zejula, Jemperli |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.